New IMB16-4 Nanoparticles Improved Oral Bioavailability and Enhanced Anti-Hepatic Fibrosis on Rats

Liver fibrosis is challenging to treat because of the lack of effective agents worldwide. Recently, we have developed a novel compound, N-(3,4,5-trichlorophenyl)-2(3-nitrobenzenesulfonamido) benzamide referred to as IMB16-4. However, its poor aqueous solubility and poor oral bioavailability obstruct...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Xia, Wang, Xiaomei, Niu, Bingyu, Wang, Yucheng, He, Hongwei, Li, Guiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781400/
https://www.ncbi.nlm.nih.gov/pubmed/35056142
http://dx.doi.org/10.3390/ph15010085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781400/
https://www.ncbi.nlm.nih.gov/pubmed/35056142
http://dx.doi.org/10.3390/ph15010085

Ejemplares similares